Japan
Heartseed Inc. is a clinical-stage biotech company known for its expertise in developing iPSC-derived highly purified ventricular cardiomyocytes, a technology poised to revolutionize the treatment of heart failure. Founded in 2015 and headquartered in Japan, the company operates at the intersection of multiple industries including Biotechnology, Health Care, and Pharmaceuticals.
Utilizing cutting-edge stem cell technology, Heartseed Inc. crafts cardiomyocyte spheroids, which are tiny clusters of heart cells transplanted surgically to enhance heart functionality. This groundbreaking approach positions the company as a leader in the care economy and wellness beauty sectors.
The company is preparing for its next stage of growth, with plans for an IPO investment on 01 July 2024. The anticipated public offering reflects confidence in Heartseed's innovative technologies and their potential to impact the global health care market significantly.
